Swedish Orphan Biovitrum AB (publ) : Sobi appoints Mats-Olof Wallin as interim Chief Financial Officer

Swedish Orphan Biovitrum AB (publ) : Sobi appoints Mats-Olof Wallin as interim
                           Chief Financial Officer

Mats-Olof Wallin has been appointed interim Chief Financial Officer at Swedish
Orphan Biovitrum AB (Sobi). Wallin - until recently the CFO of Swedish biotech
company Biotage AB (publ.) - brings more than 30 years of experience in the
pharmaceutical industry, gained from various executive positions within
companies such as Pharmacia, Ortivus and Biotage. Wallin has been working at
Sobi for the past several months.

"We are glad to welcome Mats-Olof as interim CFO. Mats-Olof brings
significant experience to the role and will join our senior team in building a
sustainable company which brings value to all stakeholders", said CEO Geoffrey

Annika Muskantor, who has been interim CFO since August 2012, will support
Mats-Olof in his new role during a transition period.

Continued McDonough: "I would like to thank Annika for her excellent work the
past year. She has built a strong financial platform which will continue to
support the development of this company."


About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on inflammation and genetic diseases, with three late stage biological
development projects within hemophilia and neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi
is a pioneer in biotechnology with world-class capabilities in protein
biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of
SEK 1.9 billion (€ 215 M) and about 480 employees. The share (STO: SOBI) is
listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com

For more information - not for
Media relations                      Investor relations
Oskar Bosson, Head of Communications Jörgen Winroth, Vice President, Head of
                                     Investor Relations
T: +46 70410 71 80                  T: +46 8 697 20 00
oskar.bosson@sobi.com                jorgen.winroth@sobi.com

Sobi press release April 8, 2013 in pdf version


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.